Xavier Montalban, MD, PhD, MBA, Vall d’Hebron University Hospital, Barcelona, Spain, discusses the clinically unmet needs in progressive multiple sclerosis (MS). Anti-inflammatory drugs such as siponimod and ocrelizumab are common therapies for progressive MS. However, there is currently a lack of neuroregenerative treatments for progressive MS that can halt or even reverse disease progression. This constitutes a critical clinical need in progressive MS. Research aiming to identify compounds with clear neuroregenerative properties is currently underway and may improve the treatment of progressive MS in the future. This interview took place during the XXV World Congress of Neurology (WCN).